SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)

被引：0
|
作者：
Paluch, Peter [1 ]
Sterclova, Martina [1 ]
Brabcova, Irena [2 ]
Viklicky, Ondrej [2 ]
Vasakova, Martina [1 ]
机构：
[1] Thomayer Hosp, Dept Resp Med, Prague 4, Czech Republic
[2] Inst Clin & Expt Med, Dept Nephrol, Prague, Czech Republic
来源：
EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷
关键词：
Interstitial lung disease; Immunology; Experimental approaches;
D O I：
10.1183/13993003.congress-2015.PA934
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA934
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The natural history of progressive fibrosing interstitial lung diseases
    Brown, Kevin K.
    Martinez, Fernando J.
    Walsh, Simon L. F.
    Thannickal, Victor J.
    Prasse, Antje
    Schlenker-Herceg, Rozsa
    Goeldner, Rainer-Georg
    Clerisme-Beaty, Emmanuelle
    Tetzlaff, Kay
    Cottin, Vincent
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
  • [42] Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
    Chen, Xianqiu
    Guo, Jian
    Yu, Dong
    Jie, Bing
    Zhou, Ying
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] The Burden of Progressive-Fibrosing Interstitial Lung Diseases
    Cottin, Vincent
    Teague, Rhiannon
    Nicholson, Lindsay
    Langham, Sue
    Baldwin, Mike
    FRONTIERS IN MEDICINE, 2022, 9
  • [44] Nintedanib for treating progressive fibrosing interstitial lung diseases
    Adler, Amanda, I
    Guo, Yelan
    Thiam, Aminata
    Elliott, Nicole
    Patel, Sanjeev
    LANCET RESPIRATORY MEDICINE, 2021, 9 (12): : E116 - E117
  • [45] Nintedanib in children and adolescents with fibrosing interstitial lung diseases
    Deterding, Robin
    Young, Lisa R.
    DeBoer, Emily M.
    Warburton, David
    Cunningham, Steven
    Schwerk, Nicolaus
    Flaherty, Kevin R.
    Brown, Kevin K.
    Dumistracel, Mihaela
    Erhardt, Elvira
    Bertulis, Julia
    Gahlemann, Martina
    Stowasser, Susanne
    Griese, Matthias
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (02)
  • [46] Imaging in the diagnosis and management of fibrosing interstitial lung diseases
    Lederer, Christoph
    Storman, Monika
    Tarnoki, Adam Domonkos
    Tarnoki, David Laszlo
    Margaritopoulos, George A.
    Prosch, Helmut
    BREATHE, 2024, 20 (01)
  • [47] Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by time since diagnosis
    Skowasch, D.
    Strek, M.
    Hallowell, W. R.
    Kus, J.
    Nunes, H.
    Suda, T.
    Tomassetti, S.
    Mueller, H.
    Rohr, B. K.
    Flaherty, R. K.
    PNEUMOLOGIE, 2022, 76 : S22 - S22
  • [48] mRNA expression of YY1, TNF-α a TGF-β in lung samples gained by transbronchial biopsies (TBB) in patients with different interstitial lung diseases (ILDs)
    Paluch, Peter
    Kolbekova, Martina
    Sterclova, Martina
    Viklicky, Ondrej
    Brabcova, Irena
    Skibova, Jelena
    Vasakova, Martina
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [49] Effects of short photoperiod on the expression of Smad2 and Smad3 mRNA in Syrian hamster testis
    Kano, K
    Kurohmaru, M
    Hayashi, Y
    Taniguchi, K
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2001, 63 (01): : 25 - 30
  • [50] Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
    Dellaripa, Paul
    Aringer, Martin
    Mann-Vold, Anna Maria Hoff
    Kelly, Clive
    Mittoo, Shikha
    James, Alexandra
    Rohr, Klaus
    Stowasser, Susanne
    Inoue, Yoshikazu
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345